Perspectives on the improvement of quality of life with epoetin alfa therapy

Epoetin alfa (recombinant human erythropoietin) effectively diminishes the anemia associated with end-stage renal disease (ESRD). Although many clinical manifestations of ESRD have been attributed to uremic toxins, the ability of epoetin alfa therapy to improve several of these conditions, such as d...

Full description

Saved in:
Bibliographic Details
Published inPharmacotherapy Vol. 10; no. 2 ( Pt 2); p. 22S
Main Authors Lundin, A P, Delano, B G, Quinn-Cefaro, R
Format Journal Article
LanguageEnglish
Published United States 01.03.1990
Subjects
Activities of Daily Living
Age Factors
Anemia - drug therapy
Appetite
Energy Metabolism
Erythropoietin - therapeutic use
Fatigue
Female
Humans
Hypothermia
Kidney Failure, Chronic - complications
Male
Physical Exertion
Quality of Life
Recombinant Proteins - therapeutic use
Sleep
Time Factors
Work Schedule Tolerance
Online AccessGet more information

Cover

More Information
Summary:Epoetin alfa (recombinant human erythropoietin) effectively diminishes the anemia associated with end-stage renal disease (ESRD). Although many clinical manifestations of ESRD have been attributed to uremic toxins, the ability of epoetin alfa therapy to improve several of these conditions, such as diminished energy levels, appetite, cold tolerance, sexual function, and cognitive abilities, suggests that anemia may be an important factor in uremia-associated symptoms. Correction of this anemia results in improvements in the patient's quality of life. These improvements can be measured by objective criteria such as exercise tolerance tests, or by subjective standards such as patient response to questionnaires. In studies to date, both subjective and objective data show that epoetin alfa therapy significantly improves the quality of life of patients with ESRD.
ISSN:0277-0008
DOI:10.1002/j.1875-9114.1990.tb02569.x